Navigation Links
Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference
Date:6/18/2009

SAN DIEGO, June 18, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Piper Jaffray Fourth Annual Europe Conference on June 23, 2009 at 9:30 a.m. British Summer Time (4:30 am Eastern Time, 1:30 a.m. Pacific Time) at the Andaz Hotel in London. Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific Officer, is scheduled to provide an overview of the company, including its clinical development and research programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Look
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Receive $100 Million from Deerfield Management
2. New arenavirus discovered as cause of hemorrhagic fever outbreak in South Africa and Zambia
3. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
4. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
5. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009
6. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
7. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
9. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
10. Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference
11. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... July 27, 2015 , ... At Champagne Smiles, they know that tooth ... can incur a lot of stress, pain, discomfort and embarrassment, which is why they ... treatment reaps the benefits of implants with the cost savings of dentures for anyone ...
(Date:7/27/2015)... ... July 27, 2015 , ... Recently, 10 Best Water ... water brands also made the organization’s list. As its name clearly indicates, 10 Best ... Here is a description of the top three brands, along with a listing of ...
(Date:7/27/2015)... ... ... In a creative effort to provide clear information about the process of ... Dove Tree in Lubbock has shared a new infographic to illustrate the process. The ... the nationally recognized collegiate program and traditional adult program at The Ranch at Dove ...
(Date:7/27/2015)... ... July 27, 2015 , ... The new ... diagnostics applications is rapidly increasing and is driven by focused research of pharmaceutical ... increasingly being evaluated for use in bio implants. MWCNTs are used in the ...
(Date:7/27/2015)... ... July 27, 2015 , ... SupplyLogic, a marketing execution ... on its newly redesigned company Website. In the blog, Founder and CEO Kevin Sherlock ... popular comedian: "Comedian George Wallace always asks: ‘Why is it the closer you get ...
Breaking Medicine News(10 mins):Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 2Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 4Health News:Best Water Brand Awards Presented by 10 Best Water 2Health News:The Ranch At Dove Tree Infographic Enlightens Process Of Recovery 2Health News:The Ranch At Dove Tree Infographic Enlightens Process Of Recovery 3Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 3Health News:SupplyLogic Releases First Executive Blog on Supply Chain Management Issues 2
... and relationships have helped many children reduce their levels of ... in August 2005, according to a new study. A second ... in the aftermath of the storm. The studies appear ... July/August 2010 issue of the journal Child Development . ...
... who survived the 2004 tsunami and ongoing civil war there ... to the youths, psychological health, but also daily stressors like ... after the disasters. The studies appear in a special ... of the journal Child Development . The first ...
... University of Texas MD Anderson Cancer Center remains the leading hospital ... according to the annual "Best Hospitals" survey published by U.S. News ... last nine years that MD Anderson has ranked number one in ... has been ranked one of the top two cancer hospitals in ...
... milk be avoided in the early months of an infant,s ... until baby starts eating solid food. But new research from ... cow,s milk in the first 15 days of life may ... Prof. Yitzhak Katz of Tel Aviv University,s Department of Pediatrics, ...
... Steven Reinberg HealthDay Reporter , WEDNESDAY, July 14 ... helps people drop pounds but does so with few side ... fighting the obesity epidemic, lorcaserin is a new type of ... associated with feelings of well-being and feeling full, and does ...
... HealthDay Reporter , WEDNESDAY, July 14 (HealthDay News) ... for Alzheimer,s disease for the first time in 25 years ... key change would put more focus on the various stages ... convened by the U.S. National Institute on Aging and the ...
Cached Medicine News:Health News:Hurricane Katrina's effects on children: Resilience and gender 2Health News:Sri Lankan children affected by war, tsunami, daily stressors 2Health News:MD Anderson keeps No. 1 cancer ranking in US News & World Report annual survey 2Health News:MD Anderson keeps No. 1 cancer ranking in US News & World Report annual survey 3Health News:Cow's milk does a baby good 2Health News:New Pill Found to Cut Weight With Few Side Effects: Study 2Health News:New Pill Found to Cut Weight With Few Side Effects: Study 3Health News:New Criteria for Alzheimer's Diagnosis Proposed 2Health News:New Criteria for Alzheimer's Diagnosis Proposed 3
(Date:7/27/2015)... DUBLIN , July 27, 2015 /PRNewswire/ ... has announced the addition of the ... Competitors And Opportunities: 2015-2020 Analysis And Forecasts" ... Comprehensive information and evaluation of the ... analysis of manufacturers, segmentation, product offerings, competitive ...
(Date:7/27/2015)...   DocResponse was ranked the most ... peer-reviewed study , "Evaluation of symptom checkers ... in the July issue of The British Medical ... School researchers determined that performance of online symptom ... diagnosis first in standardized patient evaluations more often ...
(Date:7/27/2015)... 2015 Syneron Medical Ltd. ... market leader in the aesthetic medical device marketplace, announced ... and Drug Safety (MFDS) regulatory clearance for the PicoWay® ... fulfill PicoWay orders from its Korean distribution partner, with ... the third quarter 2015. Amit Meridor, Chief ...
Breaking Medicine Technology:Global Wound Care Markets 2015-2020 - Traditonal, Advanced And Regenerative: Competitors And Opportunities 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 2Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 4
... Ortho-McNeil to Continue Investigation of GDIR Agonists Under its ... ... 7 Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today ... discovered by Arena and being investigated,for the treatment of type ...
... Phase 2 Program to Provide Initial Proof-of-Concept Data ... ... 7 VIA Pharmaceuticals,(Nasdaq: VIAP ), a biotechnology company focused ... today that,it has enrolled the first patient in its Phase 2 ...
Cached Medicine Technology:Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 2Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 3Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 4VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 2VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 3VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 4VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 5
... incubator with microprocessor-controlled 6-sided heating. Heated ... HEPA filtered CO2 inlet and fanless ... large character temperature and % CO2 ... mulitple temperature monitors ensure consistent conditions. ...
... represents the top-of-the line incubator ... against contamination is provided by ... the incubation chamber. Water for ... 60-95% r.H. is sterilized at ...
IR Autoflow Dual Chamber Over-Under Water-Jacketed CO2 Incubator...
ArcticTemp Upright Freezer -20C. Quick, even freezing. Heavy duty compressor. Deep door racks. Front gated bottom shelf. Interior light. Locks One year warranty on unit and 5 year warranty on compres...
Medicine Products: